Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts. Show more

Location: PO Box 30, Winchester, MA, 01890, United States | Website: https://www.synlogictx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

14.16M

52 Wk Range

$0.90 - $1.88

Previous Close

$1.24

Open

$1.20

Volume

2,054

Day Range

$1.20 - $1.25

Enterprise Value

-2.417M

Cash

17.27M

Avg Qtr Burn

-4.456M

Insider Ownership

11.26%

Institutional Own.

64.74%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.